First-in-human, Study of MATTISSE® Tissue Engineering Chamber in Adult Female Patients Undergoing Breast Reconstruction After Mastectomy for Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorQuanta Medical

About this trial

This study is a first in human, two-stage single arm non-comparative study of safety and performance.

The aim of the study is to asses the safety and the clinical performance of a new device : the MATTISSE tissu engineering chamber.

Eligibility criteria

Qualifiers

Female patient over 18 Years old

Immediate unilateral reconstruction after total mastectomy for early-stage breast cancer

Breast reconstruction after unilateral preventive total mastectomy

or delayed unilateral reconstruction after total mastectomy for early-stage breast cancer with a tissue expander implantation

Disqualifiers

Positive or suspicious extemporaneous sentinel node biopsy

Non integrity of LICAP and LTAP vessels, showed by the pre-operative doppler

Patient not yet implanted with MATTISSE®, whose cancer stage will finally require radiotherapy treatment

Trial design

Treatments tested in this trial

  • MATTISSE TEC

Treatment groups

50 Participants
are divided into 1 treatment group

Sponsors and collaborators

Quanta Medical

Lead sponsor

Lattice Medical

Collaborator